Zephyr Endobronchial Valve
Payments companies reported to CMS as associated with Zephyr Endobronchial Valve. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Zephyr Endobronchial Valve, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Zephyr Endobronchial Valve
These are the largest totals companies reported as associated with Zephyr Endobronchial Valve. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jonathan Kurman | Milwaukee, WI | Pulmonary Disease | $336,025.61 |
| Haley Hoy | Nashville, TN | Acute Care (Nurse Practitioner) | $320,000.46 |
| Amit Mahajan | Falls Church, VA | Internal Medicine | $256,350.61 |
| Douglas Hogarth | Chicago, IL | Pulmonary Disease | $68,614.16 |
| Rohit Goyal | Fredericksburg, VA | Critical Care Medicine (Internal Medicine) | $59,978.52 |
| Gerard Criner | Philadelphia, PA | Pulmonary Disease | $47,197.98 |
| Avi Cohen | Detroit, MI | Pulmonary Disease | $32,574.39 |
| Mark Vollenweider | Orlando, FL | Pulmonary Disease | $27,583.84 |
| Jiwoon Chang | Stanford, CA | Pulmonary Disease | $27,072.32 |
| Anil Magge | Hartford, CT | Pulmonary Disease | $21,537.55 |
Prescribed Zephyr Endobronchial Valve?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.